RET and neoplasm: In a Ba/F3 KIF5B–RET allograft tumor model, 50 mg per kg BID vepafestinib was as efficacious as 30 mg per kg selpercatinib and 60 mg per kg pralsetinib in reducing tumor burden (Extended Data Fig. 9).